These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38589688)

  • 1. Inhibition of USP7 enhances CD8
    Sun LL; Zhao LN; Sun J; Yuan HF; Wang YF; Hou CY; Lv P; Zhang HH; Yang G; Zhang NN; Zhang XD; Lu W
    Acta Pharmacol Sin; 2024 Aug; 45(8):1686-1700. PubMed ID: 38589688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocyte-derived FGL1 accelerates liver metastasis and tumor growth by inhibiting CD8+ T and NK cells.
    Xi F; Sun H; Peng H; Lian Z; Wei H; Tian Z; Sun R; Chen Y
    JCI Insight; 2024 May; 9(13):. PubMed ID: 38973608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma.
    Yang C; Qian Q; Zhao Y; Huang B; Chen R; Gong Q; Ji H; Wang C; Xia L; You Z; Zhang J; Chen X
    Front Immunol; 2023; 14():1112672. PubMed ID: 36993960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers.
    Yu ZZ; Liu YY; Zhu W; Xiao D; Huang W; Lu SS; Yi H; Zeng T; Feng XP; Yuan L; Qiu JY; Wu D; Wen Q; Zhou JH; Zhuang W; Xiao ZQ
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 37001908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding.
    Zuo D; Zhu Y; Wang K; Qin Y; Su Y; Lan S; Li Y; Dong S; Liang Y; Feng M
    Biomed Pharmacother; 2024 Jun; 175():116782. PubMed ID: 38776682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer.
    Dai X; Lu L; Deng S; Meng J; Wan C; Huang J; Sun Y; Hu Y; Wu B; Wu G; Lovell JF; Jin H; Yang K
    Theranostics; 2020; 10(20):9332-9347. PubMed ID: 32802195
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer.
    Shi AP; Tang XY; Xiong YL; Zheng KF; Liu YJ; Shi XG; Lv Y; Jiang T; Ma N; Zhao JB
    Front Immunol; 2021; 12():785091. PubMed ID: 35111155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. USP7 Enables Immune Escape of Glioma Cells by Regulating PD-L1 Expression.
    Li B; Wang B
    Immunol Invest; 2022 Oct; 51(7):1921-1937. PubMed ID: 35852892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the overexpressed USP7 inhibits esophageal squamous cell carcinoma cell growth by inducing NOXA-mediated apoptosis.
    Hu T; Zhang J; Sha B; Li M; Wang L; Zhang Y; Liu X; Dong Z; Liu Z; Li P; Chen P
    Mol Carcinog; 2019 Jan; 58(1):42-54. PubMed ID: 30182448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active site-targeted covalent irreversible inhibitors of USP7 impair the functions of Foxp3+ T-regulatory cells by promoting ubiquitination of Tip60.
    Wang F; Wang L; Wu J; Sokirniy I; Nguyen P; Bregnard T; Weinstock J; Mattern M; Bezsonova I; Hancock WW; Kumar S
    PLoS One; 2017; 12(12):e0189744. PubMed ID: 29236775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1/JAK1/FGL1 axis in lung adenocarcinoma.
    Xu T; Fang Y; Gu Y; Xu D; Hu T; Yu T; Xu YY; Shen HY; Ma P; Shu Y
    J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39384195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer.
    Li JJ; Wang JH; Tian T; Liu J; Zheng YQ; Mo HY; Sheng H; Chen YX; Wu QN; Han Y; Liao K; Pan YQ; Zeng ZL; Liu ZX; Yang W; Xu RH; Ju HQ
    Nat Commun; 2023 Oct; 14(1):6690. PubMed ID: 37872170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGL1-LAG3 axis impairs IL-10-Producing regulatory T cells associated with Systemic lupus erythematosus disease activity.
    Chen K; Li X; Shang Y; Chen D; Qu S; Shu J; Zhang M; Wang Z; Huang J; Wu M; Ming S; Wu Y
    Heliyon; 2023 Oct; 9(10):e20806. PubMed ID: 37916085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The USP7 Inhibitor P5091 Induces Cell Death in Ovarian Cancers with Different P53 Status.
    Wang M; Zhang Y; Wang T; Zhang J; Zhou Z; Sun Y; Wang S; Shi Y; Luan X; Zhang Y; Wang Y; Wang Y; Zou Z; Kang L; Liu H
    Cell Physiol Biochem; 2017; 43(5):1755-1766. PubMed ID: 29049989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells.
    Li Q; Zhang L; You W; Xu J; Dai J; Hua D; Zhang R; Yao F; Zhou S; Huang W; Dai Y; Zhang Y; Baheti T; Qian X; Pu L; Xu J; Xia Y; Zhang C; Tang J; Wang X
    Nat Commun; 2022 Dec; 13(1):7677. PubMed ID: 36509766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
    Qian W; Zhao M; Wang R; Li H
    J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ubiquitination-specific protease 7 enhances stemness of hepatocellular carcinoma by stabilizing basic transcription factor 3.
    Hu M; Dai C; Sun X; Chen Y; Xu N; Lin Z; Xu S; Cheng C; Tan Z; Bian S; Zheng W
    Funct Integr Genomics; 2024 Feb; 24(1):28. PubMed ID: 38340226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
    Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
    Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.